L-carnitine prevents progression of non-alcoholic steatohepatitis in a mouse model with upregulation of mitochondrial pathway.
Non-alcoholic steatohepatitis (NASH) is a severe form of non-alcoholic fatty liver disease characterized by lobular inflammation, hepatocellular ballooning, and fibrosis with an inherent risk for progression to cirrhosis and hepatocellular carcinoma (HCC). Mitochondrial dysfunction appears to play a...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2014-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC4077577?pdf=render |
| _version_ | 1829118642719031296 |
|---|---|
| author | Hisashi Ishikawa Akinobu Takaki Ryuichiro Tsuzaki Tetsuya Yasunaka Kazuko Koike Yasuyuki Shimomura Hiroyuki Seki Hiroshi Matsushita Yasuhiro Miyake Fusao Ikeda Hidenori Shiraha Kazuhiro Nouso Kazuhide Yamamoto |
| author_facet | Hisashi Ishikawa Akinobu Takaki Ryuichiro Tsuzaki Tetsuya Yasunaka Kazuko Koike Yasuyuki Shimomura Hiroyuki Seki Hiroshi Matsushita Yasuhiro Miyake Fusao Ikeda Hidenori Shiraha Kazuhiro Nouso Kazuhide Yamamoto |
| author_sort | Hisashi Ishikawa |
| collection | DOAJ |
| description | Non-alcoholic steatohepatitis (NASH) is a severe form of non-alcoholic fatty liver disease characterized by lobular inflammation, hepatocellular ballooning, and fibrosis with an inherent risk for progression to cirrhosis and hepatocellular carcinoma (HCC). Mitochondrial dysfunction appears to play a role in the progression from simple steatosis to NASH. L-carnitine (L-b-hydroxy-g-N-trimethylaminobutyric acid), an essential nutrient that converts fat into energy in mitochondria, has been shown to ameliorate liver damage. The aim of the present study was to explore the preventive and therapeutic effect of L-carnitine in NASH model mice. Eight-week-old male STAM mice, a NASH-cirrhosis-hepatocarcinogenic model, were divided into 3 experimental groups and fed as follows: 1) high-fat diet (HFD) (control group); 2) HFD mixed with 0.28% L-carnitine (L-carnitine group); and 3) HFD mixed with 0.01% α-tocopherol (α-tocopherol group). After 4 or 8 weeks, mice were sacrificed. Blood samples and livers were collected, and hepatic tumors were counted and measured. Livers were subjected to histological study, immunohistochemical staining of 4-hydroxynonenal and ferritin, determination of 8-OHdG levels, mRNA and protein expressions for multiple genes, and metabolomic analysis. The intestinal microbiome was also analyzed. L-carnitine increased hepatic expression of genes related to long-chain fatty acid transport, mitochondrial β-oxidation, and antioxidant enzymes following suppression of hepatic oxidative stress markers and inflammatory cytokines in NASH, and mice treated with L-carnitine developed fewer liver tumors. Although α-tocopherol resulted in NASH improvement in the same manner as L-carnitine, it increased periodontitis-related microbiotic changes and hepatic iron transport-related gene expression and led to less effective for anti-hepatocarcinogenesis. Conclusion: L-carnitine prevents progression of non-alcoholic steatohepatitis in a mouse model by upregulating the mitochondrial β-oxidation and redox system. |
| first_indexed | 2024-12-13T10:42:17Z |
| format | Article |
| id | doaj.art-dad0947e4ac54e0398d5dbc3e85d2bcf |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-13T10:42:17Z |
| publishDate | 2014-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-dad0947e4ac54e0398d5dbc3e85d2bcf2022-12-21T23:50:28ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0197e10062710.1371/journal.pone.0100627L-carnitine prevents progression of non-alcoholic steatohepatitis in a mouse model with upregulation of mitochondrial pathway.Hisashi IshikawaAkinobu TakakiRyuichiro TsuzakiTetsuya YasunakaKazuko KoikeYasuyuki ShimomuraHiroyuki SekiHiroshi MatsushitaYasuhiro MiyakeFusao IkedaHidenori ShirahaKazuhiro NousoKazuhide YamamotoNon-alcoholic steatohepatitis (NASH) is a severe form of non-alcoholic fatty liver disease characterized by lobular inflammation, hepatocellular ballooning, and fibrosis with an inherent risk for progression to cirrhosis and hepatocellular carcinoma (HCC). Mitochondrial dysfunction appears to play a role in the progression from simple steatosis to NASH. L-carnitine (L-b-hydroxy-g-N-trimethylaminobutyric acid), an essential nutrient that converts fat into energy in mitochondria, has been shown to ameliorate liver damage. The aim of the present study was to explore the preventive and therapeutic effect of L-carnitine in NASH model mice. Eight-week-old male STAM mice, a NASH-cirrhosis-hepatocarcinogenic model, were divided into 3 experimental groups and fed as follows: 1) high-fat diet (HFD) (control group); 2) HFD mixed with 0.28% L-carnitine (L-carnitine group); and 3) HFD mixed with 0.01% α-tocopherol (α-tocopherol group). After 4 or 8 weeks, mice were sacrificed. Blood samples and livers were collected, and hepatic tumors were counted and measured. Livers were subjected to histological study, immunohistochemical staining of 4-hydroxynonenal and ferritin, determination of 8-OHdG levels, mRNA and protein expressions for multiple genes, and metabolomic analysis. The intestinal microbiome was also analyzed. L-carnitine increased hepatic expression of genes related to long-chain fatty acid transport, mitochondrial β-oxidation, and antioxidant enzymes following suppression of hepatic oxidative stress markers and inflammatory cytokines in NASH, and mice treated with L-carnitine developed fewer liver tumors. Although α-tocopherol resulted in NASH improvement in the same manner as L-carnitine, it increased periodontitis-related microbiotic changes and hepatic iron transport-related gene expression and led to less effective for anti-hepatocarcinogenesis. Conclusion: L-carnitine prevents progression of non-alcoholic steatohepatitis in a mouse model by upregulating the mitochondrial β-oxidation and redox system.http://europepmc.org/articles/PMC4077577?pdf=render |
| spellingShingle | Hisashi Ishikawa Akinobu Takaki Ryuichiro Tsuzaki Tetsuya Yasunaka Kazuko Koike Yasuyuki Shimomura Hiroyuki Seki Hiroshi Matsushita Yasuhiro Miyake Fusao Ikeda Hidenori Shiraha Kazuhiro Nouso Kazuhide Yamamoto L-carnitine prevents progression of non-alcoholic steatohepatitis in a mouse model with upregulation of mitochondrial pathway. PLoS ONE |
| title | L-carnitine prevents progression of non-alcoholic steatohepatitis in a mouse model with upregulation of mitochondrial pathway. |
| title_full | L-carnitine prevents progression of non-alcoholic steatohepatitis in a mouse model with upregulation of mitochondrial pathway. |
| title_fullStr | L-carnitine prevents progression of non-alcoholic steatohepatitis in a mouse model with upregulation of mitochondrial pathway. |
| title_full_unstemmed | L-carnitine prevents progression of non-alcoholic steatohepatitis in a mouse model with upregulation of mitochondrial pathway. |
| title_short | L-carnitine prevents progression of non-alcoholic steatohepatitis in a mouse model with upregulation of mitochondrial pathway. |
| title_sort | l carnitine prevents progression of non alcoholic steatohepatitis in a mouse model with upregulation of mitochondrial pathway |
| url | http://europepmc.org/articles/PMC4077577?pdf=render |
| work_keys_str_mv | AT hisashiishikawa lcarnitinepreventsprogressionofnonalcoholicsteatohepatitisinamousemodelwithupregulationofmitochondrialpathway AT akinobutakaki lcarnitinepreventsprogressionofnonalcoholicsteatohepatitisinamousemodelwithupregulationofmitochondrialpathway AT ryuichirotsuzaki lcarnitinepreventsprogressionofnonalcoholicsteatohepatitisinamousemodelwithupregulationofmitochondrialpathway AT tetsuyayasunaka lcarnitinepreventsprogressionofnonalcoholicsteatohepatitisinamousemodelwithupregulationofmitochondrialpathway AT kazukokoike lcarnitinepreventsprogressionofnonalcoholicsteatohepatitisinamousemodelwithupregulationofmitochondrialpathway AT yasuyukishimomura lcarnitinepreventsprogressionofnonalcoholicsteatohepatitisinamousemodelwithupregulationofmitochondrialpathway AT hiroyukiseki lcarnitinepreventsprogressionofnonalcoholicsteatohepatitisinamousemodelwithupregulationofmitochondrialpathway AT hiroshimatsushita lcarnitinepreventsprogressionofnonalcoholicsteatohepatitisinamousemodelwithupregulationofmitochondrialpathway AT yasuhiromiyake lcarnitinepreventsprogressionofnonalcoholicsteatohepatitisinamousemodelwithupregulationofmitochondrialpathway AT fusaoikeda lcarnitinepreventsprogressionofnonalcoholicsteatohepatitisinamousemodelwithupregulationofmitochondrialpathway AT hidenorishiraha lcarnitinepreventsprogressionofnonalcoholicsteatohepatitisinamousemodelwithupregulationofmitochondrialpathway AT kazuhironouso lcarnitinepreventsprogressionofnonalcoholicsteatohepatitisinamousemodelwithupregulationofmitochondrialpathway AT kazuhideyamamoto lcarnitinepreventsprogressionofnonalcoholicsteatohepatitisinamousemodelwithupregulationofmitochondrialpathway |